In 2026, pharmaceutical disputes have emerged as a focal point for patent litigators, particularly in the realm of International Trade Commission (ITC) investigations. The legal landscape is shifting following the U.S. Supreme Court’s decision in Hikma v. Amarin, which addressed the implications of “skinny labels” and induced infringement. This ruling comes amid heightened scrutiny over drug imports and tariffs affecting the pharmaceutical sector.
The ITC has increasingly become a venue for life sciences companies to resolve patent disputes. Its ability to issue exclusion orders that block infringing products from entering the U.S. makes it an attractive forum for plaintiffs. However, the nuances of ITC litigation require careful strategizing.
First, it is crucial for litigants to understand the ITC’s unique procedural rules. Unlike district courts, the ITC mandates a rapid timeline for proceedings, often resolving cases within 15 to 18 months. This expedited schedule demands that litigators prepare their cases with the utmost efficiency, ensuring all necessary documentation and expert testimonies are ready well ahead of deadlines.
Another critical factor is the domestic industry requirement, a distinctive element of ITC cases. Litigants must demonstrate substantial investment in the U.S. related to the patent, which can include manufacturing, research, and development activities. This requirement not only influences case strategy but also dictates the presentation of evidence supporting the complainant’s operations in the domestic market.
The ITC’s role is further complicated by the evolving landscape of global pharmaceuticals. As international trade agreements and tariffs are negotiated, these external factors can impact the strategic considerations in ITC cases. Litigators must stay informed of geopolitical developments that may indirectly affect their trade complaints.
Additionally, there is a continuous evolution in patent law, as seen in the Hikma decision, which affects how induced infringement is interpreted in pharmaceutical cases. Understanding these legal trends is vital for constructing persuasive arguments and anticipating opposing strategies.
In conclusion, litigating life sciences investigations at the ITC involves navigating a complex web of procedural rules, patent law developments, and geopolitical factors. By staying informed and prepared, companies can leverage the ITC effectively to protect their intellectual property and market interests.